Research Topics
Genomes and Genes | Frances P O'MalleySummaryAffiliation: Mount Sinai Hospital Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Lobular neoplasia: morphology, biological potential and management in core biopsiesFrances P O'Malley
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada
Mod Pathol 23:S14-25. 2010....
Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family RegistryLetitia D Smith
Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne, Melbourne, Victoria 3010, Australia
Breast Cancer Res 13:R14. 2011..We sought to test the value of selecting women for BRCA1 mutation testing on the basis of family history and/or breast tumour morphology criteria as well as the value of testing for large genomic alterations in BRCA1...- The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancerEsther M John
Clinical and Genetic Epidemiology Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA
Breast Cancer Res 6:R375-89. 2004.... 
The spectrum of apocrine lesions of the breastF P O'Malley
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada
Adv Anat Pathol 11:1-9. 2004..Malignant apocrine lesions, including both in situ and invasive carcinoma, are also discussed...- Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breastFrances P O'Malley
Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada
Mod Pathol 19:172-9. 2006..1-97.4%), than for determining its presence (90.4%: 95% CI, 79.9-96.7%). We conclude that the diagnosis of FEA and its distinction from CCLs without atypia is highly reproducible with the use of available diagnostic criteria... - HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumabFrances P O'Malley
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Ave, Toronto, Ontario, Canada M5G 1X5
Arch Pathol Lab Med 132:61-5. 2008..Trastuzumab has been shown to only be effective in those patients whose cancers are HER2 positive by either immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH)... - An update on apocrine lesions of the breastF P O'Malley
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
Histopathology 52:3-10. 2008..This review will briefly summarize the morphological characteristics and risk associations of the spectrum of apocrine proliferations, but will focus on the updated molecular studies of both in situ and invasive apocrine carcinomas... - JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancerMichael Reedijk
Department of Surgical Oncology, University of Toronto, Toronto, ON, Canada, M5G 2M9
Breast Cancer Res Treat 111:439-48. 2008..As JAG1 is a target of several oncogenic signaling pathways, and is a ligand for Notch, these data provide novel insights into signaling that may contribute to progression of early stage breast cancer... - Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumorsAnita L Bane
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada
Breast Cancer Res Treat 117:183-91. 2009..To elucidate novel genes involved in these two spectra of breast tumorigenesis we performed global gene expression analysis on breast tumors from germline BRCA1 and BRCA2 mutation carriers... - Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohortAnna Marie Mulligan
Department of Laboratory Medicine, St Michael s Hospital, Toronto, Ontario, Canada
Clin Cancer Res 14:4168-74. 2008..Subsequent to this validation, we examined outcome in specific subgroups defined using TMA data... - EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family RegistryAnita L Bane
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
Breast Cancer Res Treat 127:831-9. 2011..EMSY amplification does occur independently of CCND1 amplification in a minority of familial breast cancers, supporting its role as a possible breast cancer oncogene... - Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort studyPamela J Goodwin
Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario
J Clin Oncol 30:19-26. 2012..To compare breast cancer prognosis in BRCA1 and BRCA2 mutation carriers with that in patients with sporadic disease... - Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancerReuben J Broom
Princess Margaret Hospital, Toronto, Canada
Anticancer Res 29:1557-62. 2009..Changes in the receptor profile between primary and metastatic breast cancer tissue have been suggested. The degree of hormone receptor discordance in archival paired pathological samples was evaluated... - CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the breast cancer family registryAnna Marie Mulligan
Keenan Research Centre in the Li Ka Shing Knowledge Institute of St Michael s Hospital and the Department of Laboratory Medicine, St Michael s Hospital, Toronto, Ontario, Canada Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
Cancer 117:1350-9. 2011.... - Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 TrialKathleen I Pritchard
Sunnybrook Odette Cancer Centre, The University of Toronto, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada
Breast Cancer Res Treat 131:541-51. 2012..5. An appropriately powered meta-analysis is required to discriminate the predictive value of these three candidate markers... - Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsyAndrea Grin
Department of Laboratory Medicine and Pathobiology, University of Toronto, Canada
Am J Surg Pathol 33:1615-23. 2009..Patterns and extent of ER and CK5 staining, when used together, are valuable adjunct stains to differentiate usual duct hyperplasia from atypical proliferations within papillary lesions on core biopsy... - Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group studyKathleen I Pritchard
Ontario Clinical Oncology Group, McMaster University, Hamilton, Canada
J Clin Oncol 30:1274-9. 2012..2-[(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) is potentially useful in assessing lymph nodes and detecting distant metastases in women with primary breast cancer... - Elevated expression of podocalyxin is associated with lymphatic invasion, basal-like phenotype, and clinical outcome in axillary lymph node-negative breast cancerCatherine L Forse
Fred A Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada
Breast Cancer Res Treat 137:709-19. 2013..001). PODXL has the potential to be a useful biomarker for identifying good prognosis patients in characteristically poor prognosis breast cancer groups and may impact treatment of women with this disease... - HER2 and responsiveness of breast cancer to adjuvant chemotherapyKathleen I Pritchard
Toronto Sunnybrook Regional Cancer Centre and the University of Toronto, Toronto, ON, Canada
N Engl J Med 354:2103-11. 2006.... - Measuring extent of ductal carcinoma in situ in breast excision specimens: a comparison of 4 methodsAndrea Grin
Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada
Arch Pathol Lab Med 133:31-7. 2009..There is no standardized method for estimating the extent of DCIS, although serial sequential sampling with mammographic correlation is considered an accurate method... - Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancerAnna Marie Mulligan
Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada
Breast Cancer Res Treat 106:39-47. 2007..Furthermore, high expression of IR is independently and significantly associated with more favorable clinical outcomes. Follow-up intervention research is recommended... - Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer RegistryAnna Marie Mulligan
Keenan Research Centre, Li Ka Shing Knowledge Institute of St Michael s Hospital, University of Toronto, Ontario, Canada
Clin Cancer Res 19:336-46. 2013..Chemokines could play a role in attracting these cells and contribute to tumor progression. We explored tumoral expression of CXCL10 and determined the relationship between CXCL10 and lymphocytic infiltrate in a cohort of breast cancers... - Papillary lesions of the breast: impact of breast pathology subspecialization on core biopsy and excision diagnosesKiran Jakate
Department of Laboratory Medicine and Pathobiology, University of Toronto, ON, Canada
Am J Surg Pathol 36:544-51. 2012.... - E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breastTeresa L Mastracci
Fred A Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada
Mod Pathol 18:741-51. 2005..These cases lacking both protein expression and gene alterations suggest that another mechanism is involved, possibly as early as at the hyperplastic stage, causing silencing of the E-cadherin complex... - A role for the TGFbeta-Par6 polarity pathway in breast cancer progressionAlicia M Viloria-Petit
Center for Systems Biology, Samuel Lunenfeld Research Institute, Room 1078 Mount Sinai Hospital, 600 University Avenue, Toronto, ON, Canada M5G 1X5
Proc Natl Acad Sci U S A 106:14028-33. 2009..These studies thus reveal a key role for polarity signaling and the control of morphologic transformation in breast cancer metastasis... - Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening programVictoria A Kirsh
Prevention and Cancer Control, Cancer Care Ontario, 620 University Ave, Toronto, ON M5G 2L7, Canada
J Natl Cancer Inst 103:942-50. 2011..Few studies have compared the prognostic value of tumor characteristics by type of breast cancer diagnosed in the interval between mammographic screenings with screen-detected breast cancers... - High-level JAG1 mRNA and protein predict poor outcome in breast cancerBrendan C Dickson
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada
Mod Pathol 20:685-93. 2007.... - Assessment of thin-layer breast aspirates for immunocytochemical evaluation of HER2 statusYvan C Bedard
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Department of Laboratory Medicine and Pathobiology, University of Toronto
Acta Cytol 47:979-84. 2003..Boxborough, Massachusetts, U.S.A.) is comparable to the findings of immunohistochemistry on corresponding surgically removed tissue... - Improving work-up of the abnormal mammogram through organized assessment: results from the ontario breast screening programMay Lynn Quan
Foothills Medical Center, University of Calgary, Calgary, Alberta Cancer Care Ontario Dalla Lana School of Public Health, University of Toronto Sunnybrook Health Sciences Centre, University of Toronto and St Michaels Hospital, University of Toronto, Toronto, Ontario, Canada
J Oncol Pract 8:107-12. 2012....